Common Stock, Shares Authorized of CRISPR Therapeutics AG from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
CRISPR Therapeutics AG quarterly Common Stock, Shares Authorized in shares history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • CRISPR Therapeutics AG Common Stock, Shares Authorized for the quarter ending 31 Dec 2025 was 132,477,166, unchanged year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Common Stock, Shares Authorized (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 132,477,166 0 0% 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q3 2025 132,477,166 0 0% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 132,477,166 0 0% 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 132,477,166 +2,024,901 +1.6% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 132,477,166 +5,940,983 +4.7% 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q3 2024 132,477,166 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 132,477,166 30 Jun 2024 10-Q 05 Aug 2024 2024 Q2
Q1 2024 130,452,265 -19,895,202 -13% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 126,536,183 -23,811,284 -16% 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q1 2023 150,347,467 +4,983,132 +3.4% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 150,347,467 +4,983,132 +3.4% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q3 2022 150,347,467 +4,983,132 +3.4% 30 Sep 2022 10-Q 01 Nov 2022 2022 Q3
Q2 2022 150,347,467 +4,983,132 +3.4% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 145,364,335 +30,191,549 +26% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 145,364,335 +30,191,549 +26% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q3 2021 145,364,335 +30,191,549 +26% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 145,364,335 +30,191,549 +26% 30 Jun 2021 10-Q 29 Jul 2021 2021 Q2
Q1 2021 115,172,786 +11,271,780 +11% 31 Mar 2021 10-Q 27 Apr 2021 2021 Q1
Q4 2020 115,172,786 +11,271,780 +11% 31 Dec 2020 10-K 15 Feb 2022 2021 FY
Q3 2020 115,172,786 +59,495,698 +107% 30 Sep 2020 10-Q 28 Oct 2020 2020 Q3
Q2 2020 115,172,786 +59,727,545 +108% 30 Jun 2020 10-Q 27 Jul 2020 2020 Q2
Q1 2020 103,901,006 +50,575,043 +95% 31 Mar 2020 10-Q 28 Apr 2020 2020 Q1
Q4 2019 103,901,006 +13,557,203 +15% 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 55,677,088 +3,783,956 +7.3% 30 Sep 2019 10-Q 28 Oct 2019 2019 Q3
Q2 2019 55,445,241 +7,924,949 +17% 30 Jun 2019 10-Q 29 Jul 2019 2019 Q2
Q1 2019 53,325,963 +6,159,056 +13% 31 Mar 2019 10-Q 29 Apr 2019 2019 Q1
Q4 2018 90,343,803 +49,250,834 +120% 31 Dec 2018 10-K 12 Feb 2020 2019 FY
Q3 2018 51,893,132 +11,002,178 +27% 30 Sep 2018 10-Q 07 Nov 2018 2018 Q3
Q2 2018 47,520,292 +6,963,401 +17% 30 Jun 2018 10-Q 07 Aug 2018 2018 Q2
Q1 2018 47,166,907 +6,908,543 +17% 31 Mar 2018 10-Q 08 May 2018 2018 Q1
Q4 2017 41,092,969 +839,295 +2.1% 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q3 2017 40,890,954 +35,228,828 +622% 30 Sep 2017 10-Q 08 Nov 2017 2017 Q3
Q2 2017 40,556,891 30 Jun 2017 10-Q 10 Aug 2017 2017 Q2
Q1 2017 40,258,364 31 Mar 2017 10-Q 11 May 2017 2017 Q1
Q4 2016 40,253,674 +34,725,595 +628% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q3 2016 5,662,126 30 Sep 2016 10-Q 22 Nov 2016 2016 Q3
Q4 2015 5,528,079 31 Dec 2015 10-K 10 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.